Adjust Font Sizing:

Jazz Pharmaceuticals Announces FDA Approval of Xywav

July 22nd, 2020

Jazz Pharmaceuticals plc announced that the US Food and Drug Administration (FDA) approved Xywav™ (calcium, magnesium, potassium, and sodium oxybates) oral solution for the treatment of cataplexy or excessive daytime sleepiness in patients 7 years of age and older with narcolepsy. Xywavis an oxybate product with 92 percent less sodium than sodium oxybate at the recommended dosage range of 6 to 9 grams.

Read the full announcement on this link.

# # #
Date Created: July 22nd, 2020
Last Updated: July 27th, 2020